Cibc World Markets Corp Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cibc World Markets Corp raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 19,153 shares of the biopharmaceutical company's stock after purchasing an additional 2,201 shares during the period. Cibc World Markets Corp's holdings in Regeneron Pharmaceuticals were worth $13,643,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after buying an additional 2,828 shares during the last quarter. Intact Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $356,000. Golden State Equity Partners grew its stake in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after acquiring an additional 1,272 shares in the last quarter. Fagan Associates Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after purchasing an additional 3,832 shares during the last quarter. Finally, ABC Arbitrage SA purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $1,510,000. 83.31% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts recently commented on REGN shares. Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Sanford C. Bernstein reduced their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target on the stock. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ REGN traded down $4.14 during trading on Friday, hitting $658.48. 1,869,092 shares of the company's stock traded hands, compared to its average volume of 632,993. The stock has a fifty day moving average of $690.20 and a two-hundred day moving average of $821.82. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The firm has a market cap of $71.99 billion, a P/E ratio of 17.20, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $11.86 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.